These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 34958142)

  • 1. Effect of montelukast therapy on clinical course, pulmonary function, and mortality in patients with COVID-19.
    Kerget B; Kerget F; Aydın M; Karaşahin Ö
    J Med Virol; 2022 May; 94(5):1950-1958. PubMed ID: 34958142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Montelukast in hospitalized patients diagnosed with COVID-19.
    Khan AR; Misdary C; Yegya-Raman N; Kim S; Narayanan N; Siddiqui S; Salgame P; Radbel J; Groote F; Michel C; Mehnert J; Hernandez C; Braciale T; Malhotra J; Gentile MA; Jabbour SK
    J Asthma; 2022 Apr; 59(4):780-786. PubMed ID: 33577360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
    Almerie MQ; Kerrigan DD
    Med Hypotheses; 2020 Oct; 143():109883. PubMed ID: 32492562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol.
    Mera-Cordero F; Bonet-Monne S; Almeda-Ortega J; García-Sangenís A; Cunillera-Puèrtolas O; Contreras-Martos S; Alvarez-Muñoz G; Monfà R; Balanzo-Joué M; Morros R; Salvador-Gonzalez B
    Trials; 2022 Jan; 23(1):19. PubMed ID: 34991703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    Copertino DC; Duarte RRR; Powell TR; de Mulder Rougvie M; Nixon DF
    J Med Virol; 2021 Jan; 93(1):187-189. PubMed ID: 32658304
    [No Abstract]   [Full Text] [Related]  

  • 6. Montelukast and Coronavirus Disease 2019: A Scoping Review.
    Sharifinejad N; Sharafian S; Salekmoghadam S; Tavakol M; Qorbani M
    Iran J Allergy Asthma Immunol; 2021 Aug; 20(4):384-393. PubMed ID: 34418892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Montelukast Inhibits HCoV-OC43 Infection as a Viral Inactivator.
    Chen Y; Wang X; Shi H; Zou P
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity.
    Al-Kuraishy HM; Al-Gareeb AI; Almulaiky YQ; Cruz-Martins N; El-Saber Batiha G
    Eur J Pharmacol; 2021 Aug; 904():174196. PubMed ID: 34004207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. As a potential treatment of COVID-19: Montelukast.
    Fidan C; Aydoğdu A
    Med Hypotheses; 2020 Sep; 142():109828. PubMed ID: 32416408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico.
    Lima-Morales R; Méndez-Hernández P; Flores YN; Osorno-Romero P; Sancho-Hernández CR; Cuecuecha-Rugerio E; Nava-Zamora A; Hernández-Galdamez DR; Romo-Dueñas DK; Salmerón J
    Int J Infect Dis; 2021 Apr; 105():598-605. PubMed ID: 33578014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies.
    Durdagi S; Avsar T; Orhan MD; Serhatli M; Balcioglu BK; Ozturk HU; Kayabolen A; Cetin Y; Aydinlik S; Bagci-Onder T; Tekin S; Demirci H; Guzel M; Akdemir A; Calis S; Oktay L; Tolu I; Butun YE; Erdemoglu E; Olkan A; Tokay N; Işık Ş; Ozcan A; Acar E; Buyukkilic S; Yumak Y
    Mol Ther; 2022 Feb; 30(2):963-974. PubMed ID: 34678509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible Therapeutic Potential of Cysteinyl Leukotriene Receptor Antagonist Montelukast in Treatment of SARS-CoV-2-Induced COVID-19.
    Dey M; Singh RK
    Pharmacology; 2021; 106(9-10):469-476. PubMed ID: 34350893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levocetirizine and montelukast in the COVID-19 treatment paradigm.
    May BC; Gallivan KH
    Int Immunopharmacol; 2022 Feb; 103():108412. PubMed ID: 34942461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effectiveness of gabapentin and gabapentin/montelukast combination compared with dextromethorphan in the improvement of COVID-19- related cough: A randomized, controlled clinical trial.
    Soltani R; Nasirharandi S; Khorvash F; Nasirian M; Dolatshahi K; Hakamifard A
    Clin Respir J; 2022 Sep; 16(9):604-610. PubMed ID: 35908849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Micro-invasive embedding combined with montelukast sodium for children cough variant asthma:a randomized controlled trial].
    Wang X; Liu B; Lu B; Zhang Y; Wang L; Li H; Han X; Ding D
    Zhongguo Zhen Jiu; 2017 Mar; 37(3):259-264. PubMed ID: 29231431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deprescribing montelukast in children with asthma: a systematic review.
    Dixon EG; King C; Lilley A; Sinha IP; Hawcutt DB
    BMJ Open; 2022 Jan; 12(1):e053112. PubMed ID: 35105629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors.
    Ma C; Wang J
    Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33568498
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.